SPL
vs
S
S&P/ASX 300
SPL
Over the past 12 months, SPL has significantly outperformed S&P/ASX 300, delivering a return of +496% compared to S&P/ASX 300's +2% growth.
Stocks Performance
SPL vs S&P/ASX 300
Performance Gap
SPL vs S&P/ASX 300
Performance By Year
SPL vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Starpharma Holdings Ltd
Glance View
Starpharma Holdings Ltd is a biotechnology company that develops and commercializes dendrimer-based products. Its best-known products are its antiviral and antibacterial gels and coatings, including women’s health products and disinfectant or surface-treatment technologies. In simple terms, it uses its chemistry platform to make products that can block germs or carry active ingredients in a more targeted way. The company sells these products directly in some markets and also licenses its technology to larger pharmaceutical, consumer health, and materials companies. That means it can earn money from product sales, license fees, and royalties when partners use its technology in their own products. Its main customers are healthcare providers, consumers, and corporate partners that need a specialized ingredient or product platform rather than a full drug discovery engine. What makes Starpharma different is that it sits between a drug developer and a technology supplier. Instead of making a broad range of medicines, it focuses on a proprietary molecular platform that can be adapted for medical, consumer, and industrial uses. This gives the business a mix of direct product revenue and partner-driven revenue, which is common in specialty biotech but less like a traditional drug maker.
